AN-7, a butyric acid prodrug, sensitizes cutaneous T-cell lymphoma cell lines to doxorubicin via inhibition of DNA double strand breaks repair Lilach MoyalNeta GoldfeizEmmilia Hodak PRECLINICAL STUDIES 08 September 2017 Pages: 1 - 9
CUDC-907, a dual HDAC and PI3K inhibitor, reverses platinum drug resistance Kenneth K. W. ToLi-wu Fu PRECLINICAL STUDIES 17 August 2017 Pages: 10 - 19
Crucial microRNAs and genes in metformin’s anti-pancreatic cancer effect explored by microRNA-mRNA integrated analysis Yilong LiLe LiBei Sun PRECLINICAL STUDIES 05 September 2017 Pages: 20 - 27
The kinesin Eg5 inhibitor K858 induces apoptosis and reverses the malignant invasive phenotype in human glioblastoma cells Ludovica TaglieriGiovanna RubinacciSusanna Scarpa PRECLINICAL STUDIES 30 September 2017 Pages: 28 - 35
A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors Janice M. MehnertGerald EdelmanPatricia M. LoRusso PHASE I STUDIES 17 April 2017 Pages: 36 - 44
Phase I study of Nedaplatin, a platinum based antineoplastic drug, combined with nab-paclitaxel in patients with advanced squamous non–small cell lung cancer Satoshi IgawaSakiko OtaniNoriyuki Masuda PHASE I STUDIES 02 May 2017 Pages: 45 - 52
A phase Ib study of everolimus combined with metformin for patients with advanced cancer Remco J. MolenaarTim van de VenneJohanna W. Wilmink PHASE I STUDIES Open access 15 June 2017 Pages: 53 - 61
Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials Jean-Marie MichotLina BenajibaVincent Ribrag PHASE I STUDIES 09 June 2017 Pages: 62 - 74
A Phase I study to determine safety, pharmacokinetics, and pharmacodynamics of ANF-RHO™, a novel PEGylated granulocyte colony-stimulating factor, in healthy volunteers Hemant MisraJohn BerrymanAbraham Abuchowski PHASE I STUDIES 28 July 2017 Pages: 75 - 84
Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors Glen J. WeissGayle JamesonRamesh K. Ramanathan PHASE I STUDIES 20 July 2017 Pages: 85 - 95
Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma Glen J. WeissLisa BlaydornVivek Khemka PHASE II STUDIES 08 November 2017 Pages: 96 - 102
A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma Sandra P. D’AngeloOmid A. HamidRichard D. Carvajal PHASE II STUDIES 11 November 2017 Pages: 103 - 113
Phase II study of doxorubicin and thalidomide in patients with refractory aggressive fibromatosis Xin LiuHuijie WangZhiguo Luo PHASE II STUDIES 23 November 2017 Pages: 114 - 120
Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads Joanna C. MastersDana J. NickensMichael Amantea REVIEW 13 October 2017 Pages: 121 - 135
Ganoderic acid, lanostanoid triterpene: a key player in apoptosis Balraj Singh GillNavgeetSanjeev Kumar REVIEW 28 October 2017 Pages: 136 - 143
A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event Francesco GelsominoGiovanni VitaleAndrea Ardizzoni SHORT REPORT 20 June 2017 Pages: 144 - 146
Chemotherapy-induced cardiomyopathy caused by Pemetrexed Takuya OyakawaKei IidaTakashi Sugino SHORT REPORT 28 June 2017 Pages: 147 - 150
Feasibility of olanzapine, multi acting receptor targeted antipsychotic agent, for the prevention of emesis caused by continuous cisplatin- or ifosfamide-based chemotherapy Seiko BunKan YonemoriKenji Tamura SHORT REPORT 21 July 2017 Pages: 151 - 155
Addition of an antiangiogenic therapy, bevacizumab, to gemcitabine plus oxaliplatin improves survival in advanced biliary tract cancers Marie BréchonMarie DiorRomain Coriat SHORT REPORT 01 August 2017 Pages: 156 - 162
Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing Kyoungmin LeeChanghoon YooBaek-Yeol Ryoo SHORT REPORT 07 August 2017 Pages: 163 - 169